Search results
AstraZeneca CEO Has No Plans to Retire as He Seeks to Nearly Double Sales by 2030
The Wall Street Journal· 23 hours agoAstraZeneca’s longest-serving chief executive, Pascal Soriot, has no plans to step down for now as...
Some drugmakers to cap cost of asthma inhalers at $35 a month
NBC News via Yahoo News· 13 hours agoStarting Saturday, the cost of inhalers will fall for many Americans, as new out-of-pocket price...
AstraZeneca (AZN) Falls on Failure to Meet NSCLC Study OS Goal
Zacks via Yahoo Finance· 3 days agoAstraZeneca's (AZN) shares decline as it fails to achieve statistically significant overall survival...
Why Is AstraZeneca Stock Trading Lower On Tuesday?
Benzinga via AOL· 4 days agoOn Tuesday, AstraZeneca Plc (NASDAQ:AZN) said the survival results did not reach statistical significance in the overall trial population in the...
This Pharma Stock Is Poised to Keep Outperforming the S&P 500
The Motley Fool via AOL· 2 days agoAstraZeneca has quietly delivered market-beating results since 2014. Despite skepticism, the company...
AstraZeneca Just Massively One-Upped Pfizer. Here's What It Means for the Stock
Motley Fool via Yahoo Finance· 3 days agoAs two of the world's largest and most prolific drugmakers, Pfizer (NYSE: PFE) and AstraZeneca...
AstraZeneca (NASDAQ:AZN) Now Covered by Analysts at The Goldman Sachs Group
ETF DAILY NEWS· 1 day agoThe Goldman Sachs Group assumed coverage on shares of AstraZeneca (NASDAQ:AZN – Free Report) in a research report report published on Thursday morning, Marketbeat Ratings ...
AstraZeneca Plans to Rake in $80 Billion by 2030. Should You Buy the Stock?
Motley Fool via Yahoo Finance· 3 days agoAstraZeneca (NASDAQ: AZN) is embarking on a fresh business plan that will see it grow significantly...
AstraZeneca-Daiichi's Enhertu follow-up Dato-DXd unable to prove overall survival benefit in phase 3
FierceBiotech· 4 days agoDaiichi Sankyo and antibody-drug conjugate (ADC) partner AstraZeneca have already filed their...
AstraZeneca stock upgraded by Goldman, 27% upside seen By Investing.com
Investing.com· 2 days agoOn Thursday, Goldman Sachs (NYSE:GS) initiated coverage on AstraZeneca (NASDAQ:AZN:LN) (NASDAQ: AZN)...